These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activated macrophages and the antitumor action of BCG. Alexander P Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313 [No Abstract] [Full Text] [Related]
8. Interaction of BCG-activated macrophages with neoplastic and nonneoplastic cell lines in vitro : quantitation of the cytotoxic reaction by release of tritiated thymidine from prelabeled target cells. Meltzer MS; Tucker RW; Sanford KK; Leonard EJ J Natl Cancer Inst; 1975 May; 54(5):1177-84. PubMed ID: 1092874 [TBL] [Abstract][Full Text] [Related]
9. Nonspecific macrophage activation by systemic adjuvants. Evaluation by lysosomal enzyme and in vitro tumoricidal activities. Bruley-Rosset M; Florentin I; Khalil AM; Mathé G Int Arch Allergy Appl Immunol; 1976; 51(5):594-607. PubMed ID: 786904 [TBL] [Abstract][Full Text] [Related]
10. [Comparative antitumoral cytostatic effect of splenic or peritoneal cells of mice with teratocarcinoma or immunized with tumoral cells. Stimulating effect of BCG and cyclophosphamide]. Christen Y C R Acad Hebd Seances Acad Sci D; 1974 Nov; 279(22):1729-32. PubMed ID: 4219181 [No Abstract] [Full Text] [Related]
11. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice. Taniyama T; Azuma I; Aladin AA; Yamamura Y Gan; 1975 Dec; 66(6):705-9. PubMed ID: 817955 [TBL] [Abstract][Full Text] [Related]
12. The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells. Poste G Am J Pathol; 1979 Aug; 96(2):595-610. PubMed ID: 382866 [TBL] [Abstract][Full Text] [Related]
13. The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract. Mathe G; Halle-Pannenko O; Florentin I; Bruley-Rosset M; Kamel M; Hiu IJ; Bourut C Eur J Cancer (1965); 1975 Nov; 11(11):801-7. PubMed ID: 767112 [No Abstract] [Full Text] [Related]
14. Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid. Chapman HA; Hibbs JB Science; 1977 Jul; 197(4300):282-5. PubMed ID: 195338 [TBL] [Abstract][Full Text] [Related]
15. BCG-induced murine effector cells. I. Cytolytic activity in peritoneal exudates: an early response to BCG. Tracey DE; Wolfe SA; Durdik JM; Henney CS J Immunol; 1977 Sep; 119(3):1145-51. PubMed ID: 330748 [No Abstract] [Full Text] [Related]
16. Studies on the antibody-dependent cell-mediated cytotoxicity (ADCC) of thioglycollate-stimulated and BCG-activated peritoneal macrophages. Koren HS; Anderson SJ; Adams DO Cell Immunol; 1981 Jan; 57(1):51-61. PubMed ID: 7011574 [No Abstract] [Full Text] [Related]
17. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro]. Reisser D; Jeannin JF; Martin F C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063 [TBL] [Abstract][Full Text] [Related]
18. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents. Germain RN; Williams RM; Benacerraf B J Natl Cancer Inst; 1975 Mar; 54(3):709-20. PubMed ID: 1091741 [TBL] [Abstract][Full Text] [Related]
19. The effect of Mycobacterium bovis (Bacillus Calmette-Guérin) on macrophage random migration, chemotaxis, and pinocytosis. Poplack DG; Sher NA; Chaparas SD; Blaese RM Cancer Res; 1976 Apr; 36(4):1233-7. PubMed ID: 769964 [TBL] [Abstract][Full Text] [Related]
20. Antileishmanial activities of macrophages from C3H/HeN and C3H/HeJ mice treated with Mycobacterium bovis strain BCG. Pappas MG; Nacy CA Cell Immunol; 1983 Sep; 80(2):217-22. PubMed ID: 6349826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]